Complications of disease and therapy: A comparison of younger and older patients with Parkinson's disease

Annals of Clinical and Laboratory Science

Volumn 26, Issue 5, 1996, Pages 389-395

  Wagner, Mary L ^a   Fedak, Mary N ^a   Sage, Jacob I ^b   Mark, Margery H ^b  

^a RUTGERS UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; CHOREA; DEMENTIA; DEPRESSION; DISEASE DURATION; DYSKINESIA; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS;

AGED; AGING; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INCIDENCE; LEVODOPA; MALE; MENTAL DISORDERS; MIDDLE AGED; PARKINSON DISEASE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 0029818869     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pederzoli M, Girotti F, Scigliano G, Aiello G, Carella F, Caraceni T. L-dopa long-term treatment in Parkinson's disease: Age-related side effects. Neurology 1983;33:1518-22.
2. Wilson JA, Smith RG. The prevalence and aetiology of long term L-dopa side effects in elderly parkinsonian patients. Age Ageing 1989;18.11-16.
3. Lieberman A, Dziatolowski M, Kupersmith M, et al. Dementia in Parkinson's disease. Ann Neurol 1979;6:355-9.
4. Mayeux R, Stern Y, Rosenstein R, et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988; 45:260-3.
5. Granérus AK, Carlsson A, Svanborg A. The aging neuron-influence on symptomatology and therapeutic response in Parkinson's syndrome. Adv Neurol 1979;24:327-34.
6. Golbe LI. Young-onset Parkinson's disease: A clinical review. Neurology 1991;41:168-73.
7. Gibb WRG, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 1988,38: 1402-6.
8. Giovannini P, Piccolo I, Genitrini S, et al. Early-onset Parkinson's disease. Mov Disord 1991;6:36-42.
9. Marttila RJ, Rinne UK. Epidemiology of Parkinson's disease- an overview. J Neural Transm Gen Sect 1981;51:135-48.
10. Marttila RJ, Rinne UK. Temporal changes in the prevalence of Parkinson's disease (abstract). Acta Neurol Scand 1990;H82(suppl 128):28.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, rev. Washington, DC: American Psychiatric Association; 1987.
12. Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: Clinical and prognostic implications. Neurology 1985;35: 522-6.
13. de Jong GJ, Meerwaldt JD, Schmitz PIM. Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 1987;22:4-7.
14. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part I. Ann Neurol 1988;24: 372-8.
15. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: Role of early treatment and disease progression. Neurology 1991;41:380-4.
16. Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991;41: 622-9.
17. Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987;13:141-78.
18. Wooten GF. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol 1988, 24:363-5.
19. Fabbrini G, Juncos J, Mouradian M, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's Disease. Ann Neurol 1987,21:370-6.
20. Lee T, Seeman P, Rajput A, Parley IJ, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 1978;273:59-61.
21. Mayeux R. Parkinson's disease: A review of cognitive and psychiatric disorders. Neuropsychiatry Neuropsychol Behav Neurol 1990;3:3-14.
22. Goetz CG, Stebboms GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-9.
23. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45:669-71.
24. Dickson DW, Ruan D, Crystal H, et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 1991;41:1402-9.
25. Sage JI, Mark MH. Diffuse Lewy body disease. In. Stern MB, Koller WC, eds. Parkinsonian syndrome. New York: Marcel Dekker, 1993: 393-411.
26. Mark MH, Dickson DW, Sage JI, Duvoisin RC. The clinicopathologic spectrum of Lewy body disease. Adv Neurol 1996;69:315-8.
27. Starkstein SE, Bertheir ML, Bolduc PL, Preziosi TJ, Robinson RG. Depression in patients with early versus late onset of Parkinson's disease. Neurology 1989;39:1441-5.
28. Kostic VS, Filipovic SR, Lecic D, Momcilovic D, Sokic D, Sternic N. Effect of age at onset on frequency of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57: 1265-7.